Jakarta - PT Indofarma Tbk (INAF) recorded a profit for the year attributable to owners of the parent entity in the first semester of 2021 of Rp977.780 million, swinging from a loss of Rp4.661 billion in the same period last year.

According to the company's financial report published on Monday (6/9), this profit-making ability was supported by strengthening net sales, which almost doubled to Rp849.325 billion from Rp447.299 billion in the corresponding period last year.

However, the cost of goods sold also strengthened by around 59.35% to Rp522.480 billion from Rp327.876 billion.

Indofarma also had to bear other losses of Rp139.402 billion for the first six months of this year. A similar period last year managed to collect a profit of Rp4,637 billion.

Financial expenses also increased by around 9.49% to Rp20.467 billion from Rp18.693 billion.

Until the first semester of 2021, Indofarma's total assets reached Rp1.951 tril